Cancer treatment | The Discreet Pharmacist

December 8, 2024

Published by TDP on December 8, 2024

New Hope for Patients with Limited-Stage Small Cell Lung Cancer: FDA Approves IMFINZI

The FDA approval of IMFINZI for limited-stage small cell lung cancer is a momentous step forward, offering a much-needed new treatment option for patients facing this aggressive disease. As the first immunotherapy regimen approved in this setting, IMFINZI has the potential to redefine care and significantly improve outcomes. This milestone underscores the importance of continued research and innovation in the fight against lung cancer.

April 12, 2024

Published by TDP on April 12, 2024

Mercaptopurine: A Cornerstone in Treating Childhood Acute Lymphoblastic Leukemia

Mercaptopurine, often referred to by its chemical name 6-mercaptopurine or simply 6-MP, stands as a pivotal medication in the oncology sphere, particularly within the context of treating childhood Acute Lymphoblastic Leukemia (ALL).

February 24, 2024

Published by TDP on February 24, 2024

The Role of Heparin in Cancer Treatment: Managing Venous Thromboembolism and Chemotherapy in Patients with Pancreatic Cancer

Heparin, available as both unfractionated and low-molecular-weight forms, has been extensively studied for its potential benefits in cancer patients. Low molecular weight heparin's role in both preventing and treating venous thromboembolism in patients, a common complication in cancer patients, has been the subject of systematic review and numerous randomized clinical trials. Furthermore, heparin has shown promising effects in managing VTE in patients undergoing cancer therapy, including those with advanced pancreatic cancer.